---
title: "301201.SZ (301201.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301201.SZ/news.md"
symbol: "301201.SZ"
name: "301201.SZ"
parent: "https://longbridge.com/en/quote/301201.SZ.md"
datetime: "2026-03-09T20:13:00.268Z"
locales:
  - [en](https://longbridge.com/en/quote/301201.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301201.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301201.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/301201.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/301201.SZ/news.md)


# 301201.SZ (301201.SZ) — Related News

### [CHENGDA PHARMA: Expected net loss of 11 million to 18 million yuan in 2025](https://longbridge.com/en/news/273958540.md)
*2026-01-28T08:34:52.000Z*
> CHENGDA PHARMA announced that it expects a net profit loss of 11 million to 18 million yuan for the fiscal year 2025. It

### [CHENGDA PHARMA: Elected Ge Jianli as Chairman](https://longbridge.com/en/news/265506957.md)
*2025-11-12T11:31:59.000Z*
> 36Kr learned that CHENGDA PHARMA announced that the board meeting agreed to elect Ge Jianli as the chairman of the compa

### [The concept of immunotherapy fluctuates strongly, with VCANBIO and others hitting the limit up](https://longbridge.com/en/news/265445813.md)
*2025-11-12T05:51:23.000Z*
> The concept of immunotherapy has fluctuated strongly, with VCANBIO and Canature Health hitting the daily limit, Chimin p

### [The cellular immunotherapy sector surged in the afternoon, with Canature Health hitting a 20% limit up](https://longbridge.com/en/news/265442846.md)
*2025-11-12T05:15:22.000Z*
> The cell immunotherapy sector surged in the afternoon, with Canature Health hitting the 20% daily limit up, Chimin, VCAN

### [CHENGDA PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 16.7733 million yuan, a decrease of 58.47%](https://longbridge.com/en/news/262883081.md)
*2025-10-27T11:32:12.000Z*
> CHENGDA PHARMA released its third-quarter report for 2025, with operating revenue of 285 million yuan in the first three

### [CHENGDA PHARMA: Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings by no more than 7.27%](https://longbridge.com/en/news/256123135.md)
*2025-09-05T11:34:10.000Z*
> CHENGDA PHARMA announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plan

### [Daily Investment and Financing Report in the Healthcare Sector (August 27): Shibeikang Completes Series B Financing](https://longbridge.com/en/news/254886305.md)
*2025-08-27T23:01:43.000Z*
> On August 27, 2025, a total of 5 investment and financing events were disclosed in the medical and health sector, involv

### [CHENGDA PHARMA invests in Shibeikang Series B financing](https://longbridge.com/en/news/254740259.md)
*2025-08-27T06:06:43.000Z*
> On August 27, 2025, CHENGDA PHARMA completed a Series B investment in Chengdu Shibeikang Biomedical Technology Co., Ltd.

### [Shibeikang announced the completion of Series B financing, with listed company CHENGDA PHARMA as the exclusive strategic investor](https://longbridge.com/en/news/254716773.md)
*2025-08-27T02:01:39.000Z*
> Recently, Chengdu Shibeikang Biopharmaceutical Technology Co., Ltd. announced the completion of its Series B financing. 

### [Shibeikang completes nearly 100 million yuan Series B financing, dedicated to innovative drug research and development](https://longbridge.com/en/news/254711801.md)
*2025-08-27T01:24:45.000Z*
> Chengdu Shibeikang Biomedicine Technology Co., Ltd. has completed nearly 100 million RMB in Series B financing, exclusiv